{
    "id": 744,
    "fullName": "MAP2K1 K57E",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MAP2K1 K57E does not lie within any known functional domains of the Map2k1 protein (UniProt.org). K57E confers a gain of function on the Map2k1 protein as demonstrated by increased activation of downstream Erk1/2 and has been associated with Braf inhibitor resistance in cell culture (PMID: 24463458, PMID: 25370473).",
            "references": [
                {
                    "id": 384,
                    "pubMedId": 24463458,
                    "title": "BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24463458"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5604,
        "geneSymbol": "MAP2K1",
        "terms": [
            "MAP2K1",
            "CFC3",
            "MAPKK1",
            "MEK1",
            "MKK1",
            "PRKMK1"
        ]
    },
    "variant": "K57E",
    "createDate": "06/16/2014",
    "updateDate": "07/01/2018",
    "referenceTranscriptCoordinates": {
        "id": 173434,
        "transcript": "NM_002755",
        "gDna": "chr15:g.66435115A>G",
        "cDna": "c.169A>G",
        "protein": "p.K57E",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 666,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP2K1 (MEK1) K57E mutations restored extracellular signal-regulated kinase (ERK) activation in the presence of Tafinlar (dabrafenib) in cultured melanoma cell lines (PMID:24463458).",
            "molecularProfile": {
                "id": 846,
                "profileName": "MAP2K1 K57E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 384,
                    "pubMedId": 24463458,
                    "title": "BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24463458"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7592,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAP2K1 K57E in a melanoma cell line harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25914,
                "profileName": "BRAF V600E MAP2K1 K57E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 846,
            "profileName": "MAP2K1 K57E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25914,
            "profileName": "BRAF V600E MAP2K1 K57E",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 173435,
            "transcript": "XM_017022411",
            "gDna": "chr15:g.66435115A>G",
            "cDna": "c.169A>G",
            "protein": "p.K57E",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 173434,
            "transcript": "NM_002755",
            "gDna": "chr15:g.66435115A>G",
            "cDna": "c.169A>G",
            "protein": "p.K57E",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}